Form 4: Pyxis Oncology Director Granted Stock Options

Pyxis Oncology Director Rachel Humphrey received a grant of 45,867 stock options with an exercise price of $1.36, vesting in one year.

Summary

• Rachel Humphrey, a Director of Pyxis Oncology, Inc. (PYXS), was granted 45,867 stock options.
• The stock options have an exercise price of $1.36 per share.
• The grant date for these options was March 24, 2026.
• The options will vest 100% on the first anniversary of the grant date, subject to continued service.
• The expiration date for these stock options is March 24, 2036.
• Following this transaction, Rachel Humphrey beneficially owns 45,867 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a routine compensation action that aligns the director's interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service to the company.

Future Outlook

The granted stock options are subject to a future vesting condition, requiring Rachel Humphrey's continued service through March 24, 2027, for the options to become fully exercisable.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options, are a standard component of executive and director compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to align the interests of company leadership with long-term shareholder value creation, a common practice among peers like Moderna (MRNA) or BioNTech (BNTX) in their compensation structures.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term performance and retention.
• The vesting schedule, typically over one to four years, is standard for such equity awards, ensuring continued commitment from the director.
• The exercise price being set at the market price on the grant date is also a standard practice for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest 100% on March 24, 2027, provided Rachel Humphrey remains in service.

Key Dates

Keywords

Pyxis Oncology, PYXS, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Vesting, SEC Form 4